Business Context and Reporting Period
Company: ImmuCell Corporation (ICCC)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2010
Business Overview: ImmuCell develops, manufactures, and sells products for the dairy and beef industries. Its primary revenue driver is First Defense (a vaccine for bovine enteritis), while it is heavily investing in the development of Mast Out (a treatment for mastitis in dairy cows).
Key Financial Metrics
| Metric | Q1 2010 | Q1 2009 |
|---|---|---|
| Total Revenues | $1,312,184 | $1,461,487 |
| Product Sales | $1,311,748 | $1,460,279 |
| Gross Margin | $739,159 (56% of sales) | $720,560 (49% of sales) |
| Net Operating Loss | $(73,962) | $(72,471) |
| Net Loss | $(53,266) | $(34,629) |
| Net Loss Per Share (Basic/Diluted) | $(0.02) | $(0.01) |
| Cash and Cash Equivalents | $1,125,081 | $1,275,162 (End of Q1 2009) |
| Short-term Investments | $3,214,000 | $3,610,000 (Dec 31, 2009) |
| Total Current Assets | $6,299,621 | $6,306,728 (Dec 31, 2009) |
| Total Current Liabilities | $371,407 | $362,770 (Dec 31, 2009) |
| Net Cash Used in Operating Activities | $(166,999) | $4,636 |
Liquidity: As of March 31, 2010, the company held approximately $4.34 million in cash and short-term investments. The company has no outstanding bank debt or open lines of credit.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 10% ($149,000) compared to Q1 2009. This was driven by a 55% drop in foreign sales, which partially offset a 4% increase in domestic sales.
- Product Mix Impact: Sales of the lead product, First Defense, decreased by 11% due to foreign market volatility. Conversely, sales of WipeOut Dairy Wipes increased by 9%.
- Margin Improvement: Despite lower sales volume, the gross margin percentage improved from 49% in Q1 2009 to 56% in Q1 2010. This was attributed to corrected biological yields from raw materials and a favorable product mix.
- Expense Increases: Sales and marketing expenses rose 32% ($41,000) due to strategic hiring. Product development expenses decreased slightly by 6% ($27,000).
- Cash Flow Deterioration: Operating cash flow shifted from a positive $4,636 in Q1 2009 to a negative $(166,999) in Q1 2010, primarily due to increased inventory levels and receivables.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Mast Out Development: The company is focused on the FDA approval of Mast Out. Positive results from the pivotal effectiveness study were announced in September 2009. The Target Animal Safety trial was completed in Q1 2010. Management intends to submit the Effectiveness and Safety sections to the FDA in Q2 2010.
- Commercialization Timeline: Assuming no delays and successful financing, a product launch for Mast Out is targeted for the latter part of 2011.
- Financing Needs: Management believes current cash resources are sufficient for operations for the next 12 months. However, external funding will be required for the commercial manufacture and launch of Mast Out. Management notes that raising equity at acceptable dilution levels is unlikely in the current market.
- Profitability Projection: The company projects a net loss for the full year 2010 due to continued investment in Mast Out development.
Risks and Contingencies
- Regulatory Risk: Approval of Mast Out is not assured. A key competitive advantage is the potential "zero milk discard" claim, which is uncertain and may not be approved by the FDA or foreign regulators (e.g., EU).
- Customer Concentration: Three distributors accounted for 47% of product sales and 51% of trade accounts receivable in Q1 2010.
- Economic Sensitivity: The company is heavily exposed to the economic health of the U.S. dairy industry, which faces low milk prices and high feed costs. This impacts customer spending power.
- Manufacturing: The company relies on a single facility in Portland, Maine, for production. Disruption here would halt operations.
Investor Verification Checklist
- Cash Runway: Verify if the $4.34 million in liquid assets is sufficient to cover the projected 2010 net loss and ongoing R&D without immediate dilution.
- FDA Submission Status: Monitor the submission dates for the Effectiveness and Target Animal Safety technical sections (expected Q2 2010) and the FDA's response timeline.
- Foreign Sales Volatility: Assess the sustainability of the 55% drop in foreign sales and the company's strategy to recover these markets.
- Customer Concentration: Review the stability of the top three distributors, who represent nearly half of the company's revenue.
- Manufacturing Financing: Confirm the status of negotiations for commercial manufacturing partners for Mast Out, as management indicated current cash may be insufficient for full-scale commercial API production.